Global BCMA Targeted Therapies Market to See Considerable Growth through 2030, Predicts Roots Analysis in Its Study Available at MarketPublishers.com
18 Apr 2017 • by Natalie Aster
LONDON – With no commercial products available, the BCMA targeted therapies market is still in its nascent stage. However, industry experts have identified considerable hopes on the new technologies currently developed by start-ups and small companies as well as the research conducted at academic institutes.
The key target indication of these new molecules is B-cell malignances, particularly multiple myeloma. BCMA targeted therapies are expected to emerge as viable treatment option for such indications.
Presently, the pipeline comprises 23 molecules, which are under development, for the treatment of different B-cell malignancies. Around 26% are currently undergoing clinical validation.
The world’s BCMA targeted therapies market is projected to experience considerable growth in the coming years. In the next decade, nearly 6 therapies are likely to become commercially available in various geographies. After the launch of the 1st products, this market is set to see tremendous growth (at an annualized rate of about 98%) through 2030.
Topical study “BCMA Targeted Therapies, 2017-2030” prepared by Roots Analysis covers the evolution of the present market and identifies the emerging growth opportunities laid down primarily by the innovative BCMA targeted programs of various pharma companies. The reports highlights more than 20 therapies targeting BCMA, which are presently in different development stages. The report covers the most important aspects of the market performance, presents insights into the pipeline, touches upon the competitive landscape and key players.
For other reports by this publisher follow to the Roots Analysis page.